“Recently I spent the afternoon with several senior executives from a large Chinese biotech company. They were all great examples of the so-called “sea turtle,” a Chinese born professional who completed their undergraduate degree in China, then left for the United States where they received both their PhD and over a decade of experience working for some of the biggest life science companies there. What brought us together was a specific question over a new innovative platform they would be bringing to market; however, we ended up spending a good bit of time discussing innovation in the life sciences in China, and what westerners many times miss when they look from the outside in at China’s various efforts to foster domestic innovation.” More available at WiCON Pharma China, here.
You are here: Home » Blog » Asia, China, Asean Healthcare Business » Inefficient Innovation in China (WiCON)
About Benjamin Shobert, MBA
Ben is the Founder and Managing Director of Rubicon Strategy Group, a consulting firm specialized in market access and project management work in China and Southeast Asia's healthcare, life science and senior care industries. Ben’s Full Bio